Puiggros, A. (Anna)

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    TP53 abnormalities are underlying the poor outcome associated with chromothripsis in chronic lymphocytic leukemia patients with complex karyotype
    (2022) Cuneo, A. (Antonio); Kamaso, J. (Joanna); Ramos-Campoy, S. (Silvia); Espinet, B. (Blanca); Oscier, D. (David); Blanco, M.L. (María Laura); Bea, S. (Silvia); Bougeon, S. (Sandrine); Baumann, T. (Tycho); Moreno, C. (Carolina); Salgado, R. (Rocío); Puiggros, A. (Anna); Gimeno, E. (Eva); Nguyen-Khac, F. (Florence); Costa, D. (Dolors); Collado, R. (Rosa); Haferlach, C. (Claudia); Rigolin, G.M. (Gian Matteo); Calvo, X. (Xavier); Parker, H. (Helen); Larrayoz, M.J. (María J.); Ancín, I. (Idoya); Schoumans, J. (Jacqueline); Strefford, J.C. (Jonathan C.); Calasanz-Abinzano, M.J. (Maria Jose); Salido, M. (Marta); Moro-García, M.A. (Marco A.)
    Simple Summary Chromothripsis, a genomic event that generates massive chromosomal rearrangements, has been described in 1-3% of CLL patients and is associated with poor prognostic factors (e.g., TP53 abnormalities and genomic complexity). However, previous studies have not assessed its role in CLL patients with complex karyotypes. Herein, we aimed to describe the genetic characteristics of 33 CLL patients with high genomic complexity and chromothripsis. Moreover, we analyzed the clinical impact of chromothripsis, comparing these patients against a cohort of 129 patients with complex karyotypes not presenting this catastrophic event. Nine cases were also assessed via the novel cytogenomic methodology known as optical genome mapping. We confirmed that this phenomenon is heterogeneous and associated with a shorter time to first treatment. Nonetheless, our findings suggested that TP53 abnormalities, rather than chromothripsis itself, underlie the dismal outcome. Chromothripsis (cth) has been associated with a dismal outcome and poor prognosis factors in patients with chronic lymphocytic leukemia (CLL). Despite being correlated with high genome instability, previous studies have not assessed the role of cth in the context of genomic complexity. Herein, we analyzed a cohort of 33 CLL patients with cth and compared them against a cohort of 129 non-cth cases with complex karyotypes. Nine cth cases were analyzed using optical genome mapping (OGM). Patterns detected by genomic ...
  • Thumbnail Image
    Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients
    (2022) Cuneo, A. (Antonio); Ramos-Campoy, S. (Silvia); Espinet, B. (Blanca); Oscier, D. (David); Blanco, M.L. (María Laura); Bea, S. (Silvia); Bougeon, S. (Sandrine); Baumann, T. (Tycho); Moreno, C. (Carolina); Bosch, F. (Francesc); Salgado, R. (Rocío); Puiggros, A. (Anna); Gimeno, E. (Eva); Nguyen-Khac, F. (Florence); Costa, D. (Dolors); Collado, R. (Rosa); Haferlach, C. (Claudia); Rigolin, G.M. (Gian Matteo); Calvo, X. (Xavier); Parker, H. (Helen); Larrayoz, M.J. (María J.); Schoumans, J. (Jacqueline); Strefford, J.C. (Jonathan C.); Calasanz-Abinzano, M.J. (Maria Jose); Ortega, M. (Margarita)
    Genome complexity has been associated with poor outcome in patients with chronic lymphocytic leukemia (CLL). Previous cooperative studies established five abnormalities as the cut-off that best predicts an adverse evolution by chromosome banding analysis (CBA) and genomic microarrays (GM). However, data comparing risk stratification by both methods are scarce. Herein, we assessed a cohort of 340 untreated CLL patients highly enriched in cases with complex karyotype (CK) (46.5%) with parallel CBA and GM studies. Abnormalities found by both techniques were compared. Prognostic stratification in three risk groups based on genomic complexity (0-2, 3- 4 and ¿5 abnormalities) was also analyzed. No significant differences in the percentage of patients in each group were detected, but only a moderate agreement was observed between methods when focusing on individual cases (kappa=0.507; P<0.001). Discordant classification was obtained in 100 patients (29.4%), including 3% classified in opposite risk groups. Most discrepancies were technique-dependent and no greater correlation in the number of abnormalities was achieved when different filtering strategies were applied for GM. Nonetheless, both methods showed a similar concordance index for prediction of time to first treatment (TTFT) (CBA: 0.67 vs. GM: 0.65) and overall survival (CBA: 0.55 vs. GM: 0.57).